KRAS and non-small cell lung carcinoma: This trial is evaluating the vaccine’s efficacy for patients with KRAS-mutant NSCLC, colorectal cancer, and pancreatic adenocarcinoma, either as a standalone treatment or alongside pembrolizumab.